RecruitingNot ApplicableNCT04350359

Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder


Sponsor

The University of Texas Health Science Center, Houston

Enrollment

120 participants

Start Date

Jun 8, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Fixed-dose TTNS Protocol, a medical device called Variable-dose TTNS Protocol 2 x week, and others for people with spinal cord injuries. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVariable-dose TTNS Protocol 5 x week

Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used.

DEVICEFixed-dose TTNS Protocol

Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. This will continue at 5x weekly until 1-year post-injury.

DEVICEVariable-dose TTNS Protocol 2 x week

At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.


Locations(2)

MedStar National Rehabilitation Hospital

Washington D.C., District of Columbia, United States

TIRR Memorial Hermann Research Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04350359


Related Trials